HC Wainwright reissued their buy rating on shares of Fate Therapeutics (NASDAQ:FATE) in a research report sent to investors on Wednesday. They currently have a $7.00 price target on the biopharmaceutical company’s stock.

FATE has been the subject of a number of other research reports. Zacks Investment Research lowered Fate Therapeutics from a buy rating to a hold rating in a research note on Wednesday, September 6th. Leerink Swann reissued an outperform rating and issued a $7.00 target price on shares of Fate Therapeutics in a research note on Friday, September 8th. BMO Capital Markets reaffirmed a buy rating and set a $7.00 price target on shares of Fate Therapeutics in a research report on Thursday, November 2nd. ValuEngine lowered Fate Therapeutics from a hold rating to a sell rating in a research report on Friday, September 22nd. Finally, Raymond James Financial reaffirmed a buy rating on shares of Fate Therapeutics in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company’s stock. Fate Therapeutics currently has a consensus rating of Buy and an average target price of $6.79.

Fate Therapeutics (FATE) traded down $0.05 during midday trading on Wednesday, hitting $4.20. The stock had a trading volume of 421,805 shares, compared to its average volume of 398,910. Fate Therapeutics has a 12 month low of $2.40 and a 12 month high of $5.68. The company has a debt-to-equity ratio of 0.32, a current ratio of 7.21 and a quick ratio of 7.21.

Fate Therapeutics (NASDAQ:FATE) last released its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.01). Fate Therapeutics had a negative net margin of 935.09% and a negative return on equity of 64.55%. The company had revenue of $1.03 million during the quarter, compared to the consensus estimate of $0.95 million. Fate Therapeutics’s revenue was up .0% on a year-over-year basis. equities research analysts forecast that Fate Therapeutics will post -0.99 earnings per share for the current year.

In other Fate Therapeutics news, insider Daniel D. Shoemaker sold 13,225 shares of the company’s stock in a transaction that occurred on Monday, October 16th. The stock was sold at an average price of $3.87, for a total transaction of $51,180.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, General Counsel Cindy Tahl sold 8,091 shares of the company’s stock in a transaction that occurred on Monday, October 16th. The shares were sold at an average price of $3.85, for a total value of $31,150.35. The disclosure for this sale can be found here. Corporate insiders own 10.88% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in FATE. New York State Common Retirement Fund bought a new position in shares of Fate Therapeutics in the 2nd quarter worth approximately $131,000. Rhumbline Advisers bought a new position in shares of Fate Therapeutics in the 2nd quarter worth approximately $133,000. Hochman Cole Investment Advisors Inc. bought a new position in shares of Fate Therapeutics in the 3rd quarter worth approximately $158,000. Schwab Charles Investment Management Inc. bought a new position in shares of Fate Therapeutics in the 2nd quarter worth approximately $214,000. Finally, California State Teachers Retirement System bought a new position in shares of Fate Therapeutics in the 2nd quarter worth approximately $219,000. 60.97% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “HC Wainwright Reaffirms Buy Rating for Fate Therapeutics (FATE)” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this article on another publication, it was illegally copied and republished in violation of United States & international trademark and copyright law. The legal version of this article can be read at https://www.watchlistnews.com/hc-wainwright-reaffirms-buy-rating-for-fate-therapeutics-fate/1768274.html.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.

Analyst Recommendations for Fate Therapeutics (NASDAQ:FATE)

Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.